Related references
Note: Only part of the references are listed.Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
Francisca Ferrer-Marin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
Tiziano Barbui et al.
LANCET HAEMATOLOGY (2021)
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
Jingshi Wang et al.
HAEMATOLOGICA (2020)
Megakaryocyte emperipolesis: a new frontier in cell-in-cell interaction
Pierre Cunin et al.
PLATELETS (2020)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N. Harrison et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Single-cell analysis based dissection of clonality in myelofibrosis
Elena Mylonas et al.
NATURE COMMUNICATIONS (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Leukemia secondary to myeloproliferative neoplasms
Andrew J. Dunbar et al.
BLOOD (2020)
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia et al.
BLOOD (2020)
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin
Yoko Edahiro et al.
CANCER SCIENCE (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Role of Inflammation and Inflammasome in Myeloproliferative Disease
Lucia Longhitano et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How et al.
CANCERS (2020)
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera
S. M. Wagner et al.
DRUGS OF TODAY (2020)
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
Alessandra Iurlo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets
Pierre Cunin et al.
ELIFE (2019)
High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN
Alexandre Guy et al.
LEUKEMIA (2019)
Platelet-Neutrophil Crosstalk in Atherothrombosis
Joachim Pircher et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
Cecilia P. Marin Oyarzun et al.
FRONTIERS IN IMMUNOLOGY (2019)
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Michael Schieber et al.
BLOOD CANCER JOURNAL (2019)
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner et al.
CELLS (2019)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Review of primary and secondary erythromelalgia
N. Mann et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2019)
Neutrophil Extracellular Traps in Arterial and Venous Thrombosis
Elodie Laridan et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Updates in the management of polycythemia vera and essential thrombocythemia
Prithvirai Bose et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2018)
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Baerbel Edelmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?
Brigitte Bauvois et al.
CANCERS (2018)
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2(V617F) Mice
Wei Wang et al.
CIRCULATION RESEARCH (2018)
Neutrophil extracellular traps in immunity and disease
Venizelos Papayannopoulos
NATURE REVIEWS IMMUNOLOGY (2018)
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
Graeme Greenfield et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Inflammation and myeloproliferative neoplasms
Federico Lussana et al.
JOURNAL OF AUTOIMMUNITY (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
N. Gupta et al.
LEUKEMIA (2017)
Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease
Giovanni Barosi et al.
LEUKEMIA RESEARCH (2017)
An emerging role for neutrophil extracellular traps in noninfectious disease
Selina K. Jorch et al.
NATURE MEDICINE (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Myeloproliferative neoplasms: from origins to outcomes
Jyoti Nangalia et al.
BLOOD (2017)
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Prithviraj Bose et al.
BLOOD (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
S. Koschmieder et al.
LEUKEMIA (2016)
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
Daria Sollazzo et al.
ONCOTARGET (2016)
Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms
Cecilia P. Marin Oyarzun et al.
SCIENTIFIC REPORTS (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells
Min Lu et al.
BLOOD (2015)
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hans Carl Hasselbalch et al.
MEDIATORS OF INFLAMMATION (2015)
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2015)
Effect of Mutation Order on Myeloproliferative Neoplasms
Christina A. Ortmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm
Veena Sangkhae et al.
BLOOD (2014)
JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2
Yuki Kagoya et al.
BLOOD (2014)
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
Mads Emil Bjorn et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms
Janine Prick et al.
EXPERIMENTAL HEMATOLOGY (2014)
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
Pontus Lundberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Christen Lykkegaard Andersen et al.
LEUKEMIA RESEARCH (2014)
A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hans C. Hasselbalch
LEUKEMIA RESEARCH (2014)
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Lorena Arranz et al.
NATURE (2014)
Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
Fabian P. Siegel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
Gilles Bonicelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Molecular basis and clonal evolution of myeloproliferative neoplasms
Ciara Cleary et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2013)
Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
Julius Wehrle et al.
HAEMATOLOGICA (2013)
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis
T. Barbui et al.
LEUKEMIA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genetic Basis of MPN: Beyond JAK2-V617F
Nicole C. C. Them et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera
Ann Mullally et al.
BLOOD (2012)
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
Peter J. Campbell et al.
BLOOD (2012)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn Scherber et al.
BLOOD (2011)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Angela G. Fleischman et al.
BLOOD (2011)
Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
Taghi Manshouri et al.
CANCER RESEARCH (2011)
Mouse models of myeloproliferative neoplasms: JAK of all grades
Juan Li et al.
DISEASE MODELS & MECHANISMS (2011)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
Tiziano Barbui et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The Thrombopoietin/MPL Pathway in Hematopoiesis and Leukemogenesis
Fu-Sheng Chou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera
Alessandro Allegra et al.
LEUKEMIA & LYMPHOMA (2011)
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F
M. Boissinot et al.
ONCOGENE (2011)
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2
Wei Wang et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and-133a
Stefanie Slezak et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2008)
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype
Thomas Stauffer Larsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
D. Colaizzo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Francois Delhommeau et al.
BLOOD (2007)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8
I Corre-Buscail et al.
EXPERIMENTAL HEMATOLOGY (2005)
Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils
A Falanga et al.
SEMINARS IN HEMATOLOGY (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
A Falanga et al.
EXPERIMENTAL HEMATOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Gene expression profiling in polycythaemia vera:: overexpression of transcription factor NF-E2
PS Goerttler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis
S Emadi et al.
BLOOD (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice
L Centurione et al.
BLOOD (2004)
Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera
S Hermouet et al.
CYTOKINE (2002)
Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythernia
C Burgaleta et al.
ACTA HAEMATOLOGICA (2002)
Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis
A Schmitt et al.
BLOOD (2000)
Share Paper
